Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced

doi: 10.31557/APJCP.2023.24.1.215

Figure Lengend Snippet: Distribution of the IFN-λ3 rs12979860 Genotypes among Healthy Subjects and Treatment- naïve HCV Chronically Infected Patients with Late Stages of Fibrosis and HCC

Article Snippet: Genotyping of the IFN-λ3 polymorphism IFN-λ3 rs12979860 was genotyped by real-time PCR using the TaqMan MGBTM probe for allelic discrimination assay (Applied Biosystems, USA) and following the manufacturer’s protocol.

Techniques: Infection

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced

doi: 10.31557/APJCP.2023.24.1.215

Figure Lengend Snippet: Distribution of the IFN-λ3 rs12979860 Genotypes and Alleles among Treatment-naïve HCV-Chronically Infected Patients with Late Stages of Fibrosis and HCC

Article Snippet: Genotyping of the IFN-λ3 polymorphism IFN-λ3 rs12979860 was genotyped by real-time PCR using the TaqMan MGBTM probe for allelic discrimination assay (Applied Biosystems, USA) and following the manufacturer’s protocol.

Techniques: Infection

Journal: Asian Pacific Journal of Cancer Prevention : APJCP

Article Title: The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced

doi: 10.31557/APJCP.2023.24.1.215

Figure Lengend Snippet: Distribution of the IFN-λ3 rs12979860 Genotypes among DAA-treated HCV-chronically Infected Patients (HCC vs no HCC development after treatment)

Article Snippet: Genotyping of the IFN-λ3 polymorphism IFN-λ3 rs12979860 was genotyped by real-time PCR using the TaqMan MGBTM probe for allelic discrimination assay (Applied Biosystems, USA) and following the manufacturer’s protocol.

Techniques: Infection

Journal: Journal of Interferon & Cytokine Research

Article Title: Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ

doi: 10.1089/jir.2018.0066

Figure Lengend Snippet: Expression Plasmids Used in This Study

Article Snippet: IFN-λ was first quantified in the serum of mice that were either injected intramuscularly with an IFN-λ3 expressing plasmid (pCS59), thus expected to produce circulating IFN-λ, or infected with mouse norovirus (Rocha-Pereira and others ).

Techniques: Expressing, Plasmid Preparation, CRISPR, Sequencing, Construct, Luciferase

Journal: Journal of Interferon & Cytokine Research

Article Title: Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-λ

doi: 10.1089/jir.2018.0066

Figure Lengend Snippet: Detection of type III IFN in biological samples by ELISA and bioassay. (A, B) IFN-λ2/3 detection by ELISA (A) and bioassay (B) in the serum of AG129 mice 2 or 4 days after electroinjection of mouse IFN-λ3 (mIFN-λ3) expressing (pCS59) or empty (pcDNA3) plasmids, 2 days after injection of pCS59, or 3 days after infection with mouse norovirus. IFN-λ detection in the serum by ELISA was performed without UV exposure to keep maximal sensitivity. (C, D) IFN-λ2/3 detection by ELISA (C) and bioassay (D) in the bronchoalveolar lavage of BALB/C mice, 5 days postinfection with RSV, compared to control mice (mock). BALF were UV-exposed before testing. (A–D) The horizontal dotted line represents the LOD. Mann–Whitney: */**indicates a significant difference compared to pcDNA3 group at days 2 or 4 (A, B) or compared to mock (D) . BALF, bronchoalveolar lavage fluid; RSV, respiratory syncytial virus.

Article Snippet: IFN-λ was first quantified in the serum of mice that were either injected intramuscularly with an IFN-λ3 expressing plasmid (pCS59), thus expected to produce circulating IFN-λ, or infected with mouse norovirus (Rocha-Pereira and others ).

Techniques: Enzyme-linked Immunosorbent Assay, Bioassay, Expressing, Injection, Infection, Control, MANN-WHITNEY, Virus

Journal: Viruses

Article Title: Interferon-λ Attenuates Rabies Virus Infection by Inducing Interferon-Stimulated Genes and Alleviating Neurological Inflammation

doi: 10.3390/v12040405

Figure Lengend Snippet: Treatment with IFN-λ inhibits RABV replication in vitro. NA or Vero cells were infected with B2c at a multiplicity of infection (MOI) of 0.01, and recombinant mouse IFN-λ2 or IFN-λ3 at 10 ng/mL and 1000 ng/mL was added to treat the B2c infected NA or Vero cells at 24 h post infection (hpi). Cell supernatants were harvested at 24 h and 48 h after the treatment for virus titration on NA cells ( A ) or Vero cells ( D ). The production of vRNA in NA cells ( B ) or Vero cells ( E) was measured by qRT-PCR. RABV N transcription levels in NA cells ( C ) or Vero cells ( F) were determined by qRT-PCR. Error bars represent the standard error (SE, n = 3). The following notations were used to indicate significant differences between groups: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Article Snippet: At 24 hpi, the cells were treated with 10 or 1000 ng/mL of IFN-λ2 or IFN-λ3 (BD Biosciences, San Jose, CA, USA) by addition into the culture medium.

Techniques: In Vitro, Infection, Recombinant, Titration, Quantitative RT-PCR

Journal: Viruses

Article Title: Interferon-λ Attenuates Rabies Virus Infection by Inducing Interferon-Stimulated Genes and Alleviating Neurological Inflammation

doi: 10.3390/v12040405

Figure Lengend Snippet: Construction and characterization of recombinant RABVs expressing IFN-λ2 or IFN-λ3. ( A ) Schematic diagram describing the construction of B2c, rB2c-IFNλ2, and rB2c-IFNλ3. The pcDNA3.1-B2c plasmid was derived from CVS-B2c by deleting the long non-coding region of the G gene and adding BsiW I and Nhe I sites between the G and L genes. Murine IFN-λ2 or IFN-λ3 coding sequences were then inserted into the RABV genome between the G and L genes. ( B ) Expression of IFN-λ2 and IFN-λ3 was measured by by ELISA. Briefly, NA cells were infected with B2c, rB2c-IFNλ2, or rB2c-IFNλ3 (MOI = 1, 0.1, 0.01, or 0.001) for 24 h, and the cell culture supernatants were then harvested to determine the quantity of murine IFN-λ2 or IFN-λ3 using a commercial ELISA kit. ( C ) BSR, NA ( D ), or Vero cells ( E ) were infected with different rRABVs at a MOI of 0.01, and multiple-step growth curves were depicted according to the viral titers at different time points. Error bars represent the SE ( n = 3). ( F ) RABV N protein expression in NA cells after infection with rRABVs. N protein was detected by western blot at 48 hpi and ratios of N/β-actin were calculated using ImageJ. ( G ) Comparison of the fluorescence morphologies of NA cells infected by different rRABVs at 48 hpi. Twenty fluorescent foci were examined to determine the number of infected cells per fluorescent focus ( H ). Scale bars represent 200 μm. Error bars represented the SE ( n = 3). The following notations were used to indicate significant differences between groups: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Article Snippet: At 24 hpi, the cells were treated with 10 or 1000 ng/mL of IFN-λ2 or IFN-λ3 (BD Biosciences, San Jose, CA, USA) by addition into the culture medium.

Techniques: Recombinant, Expressing, Plasmid Preparation, Derivative Assay, Enzyme-linked Immunosorbent Assay, Infection, Cell Culture, Western Blot, Fluorescence